Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleming, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fleming, G.

Adjuvant Therapy for High-risk Adenocarcinoma of the Uterus

Gini Fleming, MD

From the Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, Illinois

Author's disclosure of potential conflicts of interest is found at the end of this article.

Address reprint requests to Gini Fleming MD, Section of Hematology/Oncology, University of Chicago Medical Center, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637; E-mail: gfleming{at}medicine.bsd.uchicago.edu

Overview: Randomized trials have shown that radiation decreases the risk of local recurrence for high-risk stage I disease and that chemotherapy decreases the risk of recurrence for stage III disease. Trials exploring the use of chemotherapy in earlier stage disease are ongoing. Although chemotherapy is frequently used for stage I serous tumors, it remains unclear whether patients with well-staged stage I serous tumors have a higher risk than patients with stage I, grade 3 tumors. Chemotherapy may represent overtreatment for some patients, particularly patients with stage IA disease (e.g., confined to a polyp).